Biohaven Pharmaceutical Holding (BHVN) PT Raised to $87 at Cantor Fitzgerald; 'More Scarcity Value, Cash, and Pipeline Visibility'
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $87.00 (from $82.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
